Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
59 hedge funds and large institutions have $129M invested in Tourmaline Bio in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 21 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
16% more funds holding
Funds holding: 51 → 59 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.08% less ownership
Funds ownership: 7.05% → 6.97% (-0.08%)
52% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 21
55% less capital invested
Capital invested by funds: $287M → $129M (-$158M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$684K |
| 2 |
State Street
Boston,
Massachusetts
|
+$531K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$177K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$158K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$3.41M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$278K |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$221K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$169K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$113K |
TRML Hedge Fund Activity: Q2 2022 in Review
59 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q2 2022, worth a combined $129M — down 55% from $287M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TRML positions and 4 closed out — a net gain of 9 holders — while 10 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $684K. The largest seller was HHLR Advisors, cutting an estimated $3.41M.
- 59 institutional investors held Tourmaline Bio (TRML) as of Q2 2022, up from 51 in Q1 2022.
- Funds reported $129M of Tourmaline Bio stock for Q2 2022, down 55% quarter-over-quarter.
- 13 funds opened new Tourmaline Bio positions in Q2 2022 and 4 closed out, a net change of +9 holders.
- The largest Tourmaline Bio buyer in Q2 2022 was BlackRock, an estimated $684K added.
- The largest Tourmaline Bio seller in Q2 2022 was HHLR Advisors, an estimated $3.41M sold.
Based on aggregated 13F filings for Q2 2022.